Serum levels of interleukin‑6, interleukin‑10 and C‑reactive protein in patients with myocardial infarction treated with primary angioplasty during a 6‑month follow‑up

2009 ◽  
Vol 119 (3) ◽  
pp. 115-121 ◽  
Author(s):  
Łukasz Karpiński ◽  
Rafał Płaksej ◽  
Roksolana Derzhko ◽  
Alina Orda ◽  
Maria Witkowska
Keyword(s):  
Myocardial Infarction ◽  
Interleukin 6 ◽  
Serum Levels ◽  
Interleukin 10 ◽  
Primary Angioplasty ◽  
C Reactive Protein ◽  
Reactive Protein

Acute phase response after myocardial infarction: Correlation between serum levels of cytokines and C-reactive protein

1990 ◽  
Vol 68 (21) ◽  
pp. 1083-1083 ◽  
Author(s):  
H. Tilg ◽  
J. Mair ◽  
M. Herold ◽  
W. E. Aulitzky ◽  
P. Lechleitner ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Phase ◽  
Acute Phase Response ◽  
Serum Levels ◽  
Phase Response ◽  
C Reactive Protein ◽  
Reactive Protein

P4679Changes in systemic inflammation and endothelial dysfunction after balloon pulmonary angioplasty

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
W Magon ◽  
J Stepniewski ◽  
K Jonas ◽  
M Waligora ◽  
P Podolec ◽  
...  
Keyword(s):  
Endothelial Dysfunction ◽  
Serum Concentration ◽  
Systemic Inflammation ◽  
Interleukin 6 ◽  
C Reactive Protein ◽  
Pulmonary Hemodynamics ◽  
Endothelin 1 ◽  
Reactive Protein ◽  
Balloon Pulmonary Angioplasty

Abstract Introduction Pulmonary endarterectomy leads to a decrease in systemic inflammation and improvement in endothelial function in patients with chronic thromboembolic pulmonary hypertension (CTEPH). Balloon pulmonary angioplasty (BPA) improves pulmonary hemodynamics in patients with inoperable CTEPH. Aim To assess changes in systemic inflammation and endothelial dysfunction after a single BPA session and after completion of the treatment. Methods We enrolled consecutive, inoperable CTEPH patients who underwent BPA. Interleukin 6, 10 (IL-6, IL-10), and C-reactive protein (hsCRP) constituted markers of systemic inflammation. Endothelin-1 (ET-1) served as a marker of endothelial dysfunction. Serum concentration of selected markers was assessed in every patient before, 24 hours after the first BPA session and 6 months after completion of the BPA treatment. Age- and sex-matched healthy subjects served as a control group. Results We recruited 20 patients with inoperable CTEPH (6 males [30%]), aged 67 [61–74] years in New York Heart Association class III (n=19 [95%]) and II (n=1 [5%]). BPA treatment was completed with a median of 5 [2–8] BPA sessions per patient. Before starting the treatment CTEPH patients, as compared to controls (n=10), had raised serum level of IL-6 (3.82 [2.75 - 6.03] vs. 2.64 [0.88 - 4.75] pg/ml; p=0.04), hsCRP (2.47 [0.93 - 4.27] vs. 1.23 [0.48–3.21] ng/ml; p=0.02) and ET-1 (2.68 [2.24 - 3.64] vs. 1.47 [1.4 - 1.82] pg/ml; p=0.004). There was no difference in IL-10 level. 24 hours after a BPA session we observed an increased level of IL-6, IL-10 and hsCRP. (Tab.) 6 months after completion of the BPA treatment there was a reduced level of IL-6, hsCRP and ET-1 (Tab.) Table 1. Changes (Δ) in serum concentration of analyzed markers 24 hours after a single BPA session and at 6-months assessment after completion of the BPA treatment (n=20) Initial Δ at 24 hours after single BPA p Δ at 6-months follow-up p ET-1 [pg/ml] 2.68 [2.24; 3.64] −0.2 [−0.5; 0.23] 0.21 −0.47 [−0.96; 0.05] 0.004 IL-6 [pg/ml] 3.82 [2.75; 6.03] 3.67 [1.41; 7.16] 0.008 −0.82 [−3.11; 0.54] 0.04 IL-10 [pg/ml] 0.53 [0.44; 0.58] 0.32 [0.21; 0.87] 0.006 −0.11 [−0.33; 0.14] 0.94 hsCRP [ng/ml] 2.47 [0.93; 4.27] 5.4 [3.96; 10.59] 0.008 −0.36 [−0.94; 0.16] 0.02 ET-1, endothelin 1; hsCRP, C-reactive protein; IL-6, interleukin 6; IL-10, interleukin 10. Conclusions Patients with inoperable CTEPH, as compared to healthy controls, exhibit an increased systemic inflammation and endothelial dysfunction, which both improve after completion of the BPA treatment. At short-term follow-up after single BPA session there is an increase in systemic inflammatory response.

scholarly journals The effect of treatment with N-acetylcysteine on the serum levels of C-reactive protein and interleukin-6 in patients on hemodialysis

2014 ◽  
Vol 25 (1) ◽  
pp. 66 ◽  
Author(s):  
Fereshteh Saddadi ◽  
Sudabeh Alatab ◽  
Farahnaz Pasha ◽  
MohammadReza Ganji ◽  
Tayebeh Soleimanian
Keyword(s):  
Interleukin 6 ◽  
Serum Levels ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Effect Of Treatment

scholarly journals Three-year follow-up of Interleukin 6 and C-reactive protein in chronic obstructive pulmonary disease

2013 ◽  
Vol 14 (1) ◽  
pp. 24 ◽  
Author(s):  
Renata Ferrari ◽  
Suzana E Tanni ◽  
Laura MO Caram ◽  
Corina Corrêa ◽  
Camila R Corrêa ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Interleukin 6 ◽  
Chronic Obstructive ◽  
C Reactive Protein ◽  
Obstructive Pulmonary Disease ◽  
Reactive Protein

scholarly journals Effects of metformin treatment on serum levels of C-reactive protein and interleukin-6 in women with polycystic ovary syndrome

Medicine ◽  
2017 ◽  
Vol 96 (39) ◽  
pp. e8183 ◽  
Author(s):  
Jiao Wang ◽  
Lingyan Zhu ◽  
Kaixiang Hu ◽  
Yunliang Tang ◽  
Xiangxia Zeng ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Interleukin 6 ◽  
Polycystic Ovary ◽  
Serum Levels ◽  
Metformin Treatment ◽  
C Reactive Protein ◽  
Ovary Syndrome ◽  
Reactive Protein

Serum Levels of Interleukin-6 and C-Reactive Protein Correlate With Body Mass Index Across the Broad Range of Obesity

2004 ◽  
Vol 28 (6) ◽  
pp. 410-415 ◽  
Author(s):  
Lalita Khaodhiar ◽  
Pei-Ra Ling ◽  
George L. Blackburn ◽  
Bruce R. Bistrian
Keyword(s):  
Body Mass Index ◽  
Body Mass ◽  
Interleukin 6 ◽  
Serum Levels ◽  
C Reactive Protein ◽  
Reactive Protein

scholarly journals Comparative Effect of Aspirin, Meloxicam and Terminalia catappa Leaf Extract on Serum Levels of Some Inflammatory Markers in Alloxan Induced Diabetic Rats

2019 ◽  
pp. 1-10
Author(s):  
Ezekiel E. Ben ◽  
Asuquo E. Asuquo ◽  
Daniel U. Owu
Keyword(s):  
Body Weight ◽  
Interleukin 6 ◽  
Leaf Extract ◽  
Serum Levels ◽  
Diabetic Rats ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Terminalia Catappa ◽  
Aqueous Leaf Extract ◽  
Anti Inflammatory

Background: The association between diabetes mellitus and inflammation is established but the use of non-steroidal anti-inflammatory drugs is not without some health risk. Aim: The study was aimed at comparing the levels of some inflammatory biomarkers in diabetic rats treated with aqueous leaf extract of Terminalia catappa, non steroidal anti-inflammatory drugs (NSAIDs) and exogenous insulin. Materials and Methods: Thirty six (36) Wistar rats were assigned to 6 groups of 6 animals each. Group 1 and 2 served as normal and diabetic controls and received orally 5ml/kg body weight of distilled water. Group 3 was diabetic treated orally with 130mg/kg body weight of aqueous leaf extract of Terminalia catappa.  And groups 4, 5 and 6 were administered orally with aspirin (30mg/kg), meloxicam (2mg/kg) and 0.75U/kg body weight of insulin subcutaneously. Diabetes was induced with intraperitoneal injection of 150mg/kg body weight of alloxan solution and diabetes confirmed after 72 hours with blood glucose levels ≥200mg/dl. The experiment lasted for 14 days and blood was collected by cardiac puncture for serum analysis of C-reactive protein, Interleukin-6 and Fibrinogen by ELISA method. Results: The results showed significant (P<0.05) increase in serum levels of C-reactive protein, Interleukin-6 and blood fibrinogen in diabetic group compared to control. These inflammatory biomarker were significantly (P<0.05) reduced by the extract, aspirin, meloxicam and insulin.  Conclusion: The reduced levels of C-reactive protein, Interleukin-6 and fibrinogen by aqueous leaf extract of Terminalia catappa was significant compared to aspirin and meloxicam. This may present the extract as a potent anti-inflammatory agent and could complement the function of insulin in diabetes treatment.

Sign in / Sign up

Export Citation Format

Share Document